GET DAILY SIGNALSTempest Therapeutics (TPST) Q3 Earnings Preview: Liquidity and Pipeline Updates in Focus
Key Takeaways
- Tempest Therapeutics (TPST) is expected to report results for its fiscal third quarter ended September 30, 2026, with a consensus net loss estimate of $0.32 per share, according to Wall Street estimates.
- As a clinical-stage biotechnology company with no approved products, Tempest is not expected to generate product revenue; the focus is on operating loss, cash burn, and pipeline updates.
- The company has pivoted to in vivo CAR-T therapies — treatments that program a patient's immune cells inside the body rather than in a lab — following its February 2026 acquisition of Erigen CAR-T assets.
- Liquidity is the dominant concern: Tempest held roughly $0.8 million in cash as of June 30, 2026, and its auditors have flagged substantial doubt about its ability to continue as a going concern.
- The prior quarter (Q2 2026) delivered a wider-than-expected loss of $0.34 per share versus a $0.30 consensus estimate, pressuring the stock to levels near its 52-week low.
- For additional detail on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages.
- Explore Trending AI Robots to see how AI-driven strategies are tracking this and other names.
Earnings Context and Why It Matters
Tempest Therapeutics (TPST) heads into its third-quarter report at a critical juncture. The company has moved away from small-molecule cancer drug development and toward a dual-targeting in vivo CAR-T platform built around candidates TPST-2003 and TPST-4003. Early data on TPST-2003 showed a 100% complete response rate in a small group of 15 patients, yet the more immediate issue remains the balance sheet. With limited cash, a related-party funding arrangement linked to CEO Matt Angel’s affiliate Factor Bioscience, and Nasdaq listing-compliance questions, this update will likely highlight plans for funding upcoming clinical work. In my view, the earnings release centers less on near-term profits and more on survival, financing, and execution.
Earnings Expectations
Wall Street’s consensus points to a net loss of $0.32 per share for the fiscal third quarter ended September 30, 2026, drawn from a single covering analyst. With no commercial products, revenue is projected at $0, so attention will fall on operating loss and cash usage rather than sales figures. Historical results add perspective: in Q2 2026, Tempest reported a diluted loss of $0.34 per share, missing the $0.30 consensus by roughly 13%. That came after a Q1 2026 loss of $0.50 per share against a $0.28 estimate. The June 30, 2026 cash balance of about $0.8 million, down from $7.7 million at the end of 2025, shows how quickly liquidity has declined. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors will monitor any updated cash position, new financing details, and commentary on the Factor Bioscience commitment.
Market Reaction and Investor Sentiment
Sentiment ahead of the report remains cautious. Shares of Tempest Therapeutics (TPST) have hovered near the 52-week low around $0.50, reflecting a year-to-date drop of roughly 79%. Post-earnings moves have been volatile, and the two most recent quarters both produced misses that have weighed on confidence. H.C. Wainwright lowered its price target to $7 from $11 in September 2026, while the company postponed its special stockholder meeting due to insufficient votes on governance changes. Financing risk stays the primary concern, and any signal on new capital, the going-concern warning, or Nasdaq compliance could trigger a sharp reaction.
Forward Outlook and Key Factors to Monitor
Funding stands out as the clearest item to watch after the report. With roughly $0.8 million in cash at mid-year and ongoing losses, Tempest’s progress on its CAR-T programs hinges on raising additional capital through equity sales, warrant exercises, or the Factor Bioscience arrangement. Clinical pipeline updates also matter. TPST-2003 has shown promising early responses in relapsed/refractory multiple myeloma, and management plans an IND filing with the FDA in the fourth quarter of 2026. The July 2026 collaboration with Senlang Biotechnology extends TPST-4003 development into the Chinese autoimmune market. Regulatory and governance items complete the list: Tempest remains non-compliant with certain Nasdaq requirements on stockholders’ equity and audit committee composition, and the special meeting is now set for November 2026. Updates on these areas, along with cash runway and dilution, will influence how the path forward is viewed.
AI Tools in My Research Process
I frequently turn to Tickeron’s AI Screener when evaluating clinical-stage names like this one. The tool lets me apply filters for technical patterns, fundamentals, and sector trends to quickly surface comparable ideas and monitor shifts in sentiment across biotech. It helps keep the analysis grounded without replacing core fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for TPST turns negative, indicating new downward trend
TPST saw its Momentum Indicator move below the 0 level on October 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In 72 of the 79 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TPST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TPST entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +4.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where TPST advanced for three days, in 178 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
TPST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-7.261) is normal, around the industry mean (3.051). P/E Ratio (-0.127) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. TPST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TPST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceuticals
Industry Biotechnology
Advertisement